原發性硬化性膽管炎市場按藥物類別、給藥途徑、分銷管道和地區分類

2025 年全球原發性硬化性膽管炎市場規模估計為 1.741 億美元，預計到 2032 年將達到 2.986 億美元，2025 年至 2032 年的複合年成長率為 8.0%。

數字。 2025 年原發性硬化性膽管炎市場佔有率（%），依地區分類

原發性硬化性膽管炎 (PSC) 是一種慢性進行性膽汁淤積性肝病，其特徵是肝內和肝外膽管多灶性狹窄和纖維化。 70-80％的病例伴隨發炎性腸道疾病腸道疾病，通常是潰瘍性大腸炎。 PSC 的具體病因尚不清楚，但人們認為它是一種由遺傳易感性和環境觸發因素的複雜相互作用導致的自體免疫疾病。全球原發性硬化性膽管炎的盛行率估計為每十萬人有13至16例。目前，PSC 尚無治療方法，治療重點是緩解症狀和減緩病情進展。全球原發性硬化性膽管炎市場的成長是由診斷率的上升和醫療保健支出的增加所推動的。

市場動態

全球原發性硬化性膽管炎市場的成長受到多種因素的推動，例如人們對該疾病的認知不斷提高、由於診斷方法的進步而導致的診斷率上升、以及全球易患原發性硬化性膽管炎的老年人口增加。然而，缺乏核准用於治療 PSC 的藥物和複雜的致病機制可能會阻礙市場的成長。正在進行的新療法研發和新興市場不斷上升的醫療成本可能為市場參與企業創造巨大的商機。

研究的主要特點

本報告對全球原發性硬化性膽管炎市場進行了詳細分析，並以 2024 年為基準年，給出了預測期（2025-2032 年）的市場規模和年複合成長率（CAGR%）。

它還揭示了各個領域的潛在商機並解釋了該市場的引人注目的投資提案矩陣。

它還提供了對市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的重要見解。

全球原發性硬化性膽管炎市場的主要企業根據公司亮點、產品系列、關鍵亮點、財務表現和策略等參數進行分析。

本研究涉及的主要企業包括 Intercept Pharmaceuticals、Dr. Falk Pharma GmbH 和 Acorda Therapeutics Inc.

本報告的見解將使負責人和公司經營團隊能夠就未來的產品發布、規模擴大、市場擴張和行銷策略做出明智的決策。

全球原發性硬化性膽管炎市場報告迎合了該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。

相關人員將透過全球原發性硬化性膽管炎市場分析中使用的各種策略矩陣來做出決策。

目錄

第1章 調查目的與前提條件

• 研究目標
• 先決條件
• 簡稱

第2章 市場展望

• 報告描述
  • 市場定義和範圍
• 執行摘要
• 一致的機會圖 (COM)

第3章市場動態、法規與趨勢分析

• 市場動態
  • 驅動程式
  • 限制因素
  • 機會
• 影響分析
• 市場趨勢
• 監管情景
• 收購和合作場景
• 資金籌措和投資
• PEST分析
• 波特的分析

第4章 全球原發性硬化性膽管炎市場-冠狀病毒 (COVID-19) 大流行的影響

• 整體影響
• 政府舉措
• COVID-19 市場影響

5. 2020-2032 年全球原發性硬化性膽管炎市場（依藥物類別分類）（百萬美元）

• 介紹
• 熊去氧膽酸（UDCA）
• 皮質類固醇
• Azathioprine
• Mercaptopurine
• Budesonide
• 奧貝膽酸
• 單株抗體
• 其他

6. 2020-2032 年全球原發性硬化性膽管炎市場，依給藥途徑分類（百萬美元）

• 介紹
• 口服
• 腸外
• 其他

7. 2020-2032 年全球原發性硬化性膽管炎市場按分銷管道分類（百萬美元）

• 介紹
• 醫院藥房
• 零售藥局
• 網路藥局

8. 2020 年至 2032 年全球原發性硬化性膽管炎市場（按地區分類）（百萬美元）

• 介紹
• 北美洲
• 拉丁美洲
• 歐洲
• 亞太地區
• 中東
• 非洲

第9章 競爭格局

• 公司簡介
  • Acorda Therapeutics, Inc.
  • Gilead Sciences, Inc.
  • NGM Biopharmaceuticals, Inc.
  • Intercept Pharmaceuticals, Inc.
  • Dr. Falk Pharma GmbH
  • Allergan Plc.
  • Shire Plc.
  • Durect Corporation
  • Conatus Pharmaceuticals, Inc.
  • Sirnaomics, Inc.
  • Shenzhen HighTide Biopharmaceutical Ltd.
  • Cymabay Therapeutics
  • Pliant Therapeutics
  • Immunic AG

第 10 章分析師建議

• 興衰
• 一致的機會地圖

第 11 章 參考文獻與調查方法

• 參考
• 調查方法

Global Primary Sclerosing Cholangitis Market is estimated to be valued at USD 174.1 Mn in 2025 and is expected to reach USD 298.6 Mn by 2032, growing at a compound annual growth rate (CAGR) of 8.0% from 2025 to 2032.

Figure. Primary Sclerosing Cholangitis Market Share (%), By Region 2025

Primary sclerosing cholangitis (PSC) is a chronic progressive cholestatic liver disease characterized by multifocal strictures and fibrosis of the intrahepatic and extrahepatic bile ducts. It is associated with inflammatory bowel disease, usually ulcerative colitis, in 70-80% of cases. The exact cause of PSC remains unknown, but it is believed to be an autoimmune disease resulting from a complex interplay between genetic susceptibility and environmental triggers. The global prevalence of PSC is estimated to range between 13-16 cases per 100,000 individuals. Currently, there is no cure for PSC and treatment is focused on relieving symptoms and slowing disease progression. Global primary sclerosing cholangitis market growth is driven by increasing diagnosis rates and rising healthcare expenditure.

Market Dynamics:

Global primary sclerosing cholangitis market growthis driven by factors like rising awareness about the disease, increasing diagnosis rates attributed to advanced diagnostic modalities, and growing geriatric population worldwide who are more susceptible to develop PSC. However, lack of an approved drug for treating PSC and complexities associated with the disease pathogenesis can hamper the market growth. Ongoing R&D for developing novel therapeutics and increasing healthcare expenditures in emerging nations can present high-impact profitable opportunities for market players.

Key Features of the Study:

This report provides in-depth analysis of the global primary sclerosing cholangitis market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global primary sclerosing cholangitis market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Intercept Pharmaceuticals, Dr. Falk Pharma GmbH, and Acorda Therapeutics Inc.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global primary sclerosing cholangitis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global primary sclerosing cholangitis market

Detailed Segmentation-

• By Drug Class
  • Ursodeoxycholic acid (UDCA)
  • Corticosteroids
  • Azathioprine
  • Mercaptopurine
  • Budesonide
  • Obeticholic acid
  • Monoclonal antibody
  • Others
• By Route of Administration
  • Oral
  • Parenteral
  • Others
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Acorda Therapeutics, Inc.
  • Gilead Sciences, Inc.
  • NGM Biopharmaceuticals, Inc.
  • Intercept Pharmaceuticals, Inc.
  • Falk Pharma GmbH
  • Allergan Plc.
  • Shire Plc.
  • Durect Corporation
  • Conatus Pharmaceuticals, Inc.
  • Sirnaomics, Inc.
  • Shenzhen HighTide Biopharmaceutical Ltd.
  • Cymabay Therapeutics
  • Pliant Therapeutics
  • Immunic AG

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Class
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Acquisitions and Partnerships Scenario
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Primary Sclerosing Cholangitis Market- Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Primary Sclerosing Cholangitis Market, By Drug Class, 2020 - 2032, (USD Mn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Ursodeoxycholic acid (UDCA)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Corticosteroids
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Azathioprine
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Mercaptopurine
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Budesonide
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Obeticholic acid
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Monoclonal antibody
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

6. Global Primary Sclerosing Cholangitis Market, By Route of Administration, 2020 - 2032, (USD Mn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Parenteral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

7. Global Primary Sclerosing Cholangitis Market, By Distribution Channel, 2020 - 2032, (USD Mn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

8. Global Primary Sclerosing Cholangitis Market, By Region, 2020 - 2032, (USD Mn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2020-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Mn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Company Profiles
  • Acorda Therapeutics, Inc.
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Gilead Sciences, Inc.
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • NGM Biopharmaceuticals, Inc.
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Intercept Pharmaceuticals, Inc.
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Dr. Falk Pharma GmbH
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Allergan Plc.
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Shire Plc.
  • Durect Corporation
  • Conatus Pharmaceuticals, Inc.
  • Sirnaomics, Inc.
  • Shenzhen HighTide Biopharmaceutical Ltd.
  • Cymabay Therapeutics
  • Pliant Therapeutics
  • Immunic AG

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About Us and Sales Contact